19 NOVEMBER 2026 ASX RELEASE ETHICS APPROVAL FOR AMPLIA’S ACCENT-MINI TRIAL HIGHLIGHTS • Ethics approval received for ACCENT-Mini, evaluating daily-dosed narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer • The trial builds on encouraging ACCENT results, including a...
Ethics Approval for Amplia's ACCENT-Mini Trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. has received ethics approval for its ACCENT-Mini trial, which will evaluate the combination of narmafotinib with gemcitabine and Abraxane in metastatic pancreatic cancer. This trial builds on previous encouraging results from the ACCENT trial, which showed improved outcomes compared to chemotherapy alone. Safety and pharmacokinetic data from the ACCENT-Mini trial are expected to support a future FDA protocol submission. The trial is a significant step in Amplia's strategy to enhance treatment options for difficult-to-treat cancers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Amplia Receives R&D Tax Rebate Totalling $4.78 Million
- Amplia Therapeutics Provides Clinical Trial Updates
- Response to ASX Price Query
- Amplia Presents at CG Drug and Device Conference 2026
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics